Comparative Pharmacology
Head-to-head clinical analysis: ANSAID versus NAPROXEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSAID versus NAPROXEN SODIUM.
ANSAID vs NAPROXEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
200-300 mg orally or rectally twice daily, or 100 mg orally three times daily; maximum 300 mg/day.
220-550 mg orally twice daily; maximum 1375 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours. No accumulation occurs with normal dosing; however, in elderly or hepatic impairment, half-life may be prolonged.
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Renal excretion of metabolites (approximately 95%), with less than 5% excreted unchanged. Fecal elimination accounts for minor amounts.
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Category C
Category D/X
NSAID
NSAID